In this episode of "In the Interim…", Dr. Scott Berry, Dr. Elizabeth Lorenzi, and Dr. Amy Crawford discuss the STEP platform trial’s statistical methodology for evaluating which acute stroke patients benefit and which do not from endovascular therapy (EVT).

Bayesian statistics enables efficient, inclusive, and compliant clinical trial designs by rigorously updating evidence, supporting adaptation, and enabling comprehensive analysis across complex data landscapes.

This episode of "In the Interim…" features Dr. Scott Berry, Dr. Kert Viele, and Dr. Melanie Quintana of Berry Consultants dissecting the technical and operational landscape of Bayesian statistics in clinical trial design.

The “time machine” enables rigorous, unbiased comparisons in adaptive platform trials by modeling era effects and overlapping treatments, improving resource allocation while ensuring accurate estimation.

Berry Consultants is proud to sponsor next week’s American Statistical Association 2025 Joint Statistical Meetings (JSM) in Nashville, Tennessee!

Dr. Scott Berry and Dr. Kert Viele discuss the origins and implementation of the “time machine” modeling approach, beginning with sports analytics and progressing to adaptive platform clinical trials.